USPTO Awards Another Patent; New Data Demonstrating 14-3-3η as a Biomarker for Monitoring Therapy Response

USPTO Awards Patent for Citrullinated 14-3-3: Expanding Augurex’s Portfolio in the Diagnosis of Rheumatoid Arthritis (RA)

On November 20^th, 2018 the US Patent and Trademark Office (USPTO) awarded patent number 10,132,806 entitled “Antigens Derived From Citrullinated 14-3-3 And Uses Thereof In The Diagnosis of Rheumatoid Arthritis.” Citrullinated 14-3-3η auto-antibodies are expressed in early and established RA and complement ACPA as a diagnostic aid. It’s hypothesized that patients with elevated levels of circulating citrullinated 14-3-3η may have a more favorable prognosis. 14-3-3η continues to pave the way for a future with better patient outcomes.

New published data demonstrating 14-3-3η as a biomarker for monitoring Tofacitinib therapy response in RA patients

14-3-3η is a modifiable marker of joint damage progression risk, which makes it ideal to track over time for the optimization of RA treat-to-target strategies to improve clinical and radiographic outcomes. The newly published study demonstrates how changes in 14-3-3η levels correlate with clinical disease activity measures in RA patients treated with Tofacitinib. It is expected that 14-3-3η will have an increasingly important role in the management of RA patients and this study highlighted 14-3-3η as a biomarker for monitoring therapy response. Read more